Please login to the form below
5
Revenue 2017Avastin
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Avastin was produced by Roche.
ASCO: Merck’s Keytruda tops chemo in MSI-H colorectal cancer
Investigators could choose the chemotherapy-based regimen they used as the comparator in the trial, and a number opted for the combination of Roche’s Avastin (bevacizumab) with mFOLFOX6, which is
AZ’s comeback drug cediranib stumbles in phase 3 trial
Cediranib has been developed as a potential oral alternative to drugs like Roche’s big-selling injectable VEGF inhibitor Avastin (bevacizumab), which is already used to treat ovarian cancer and other
FDA accepts review to broaden GSK’s Zejula label
Lynparza, like Zejula, has data which backs up its use in ‘all-comer’ ovarian cancer patients – when added to Avastin (bevacizumab), the standard of care for ovarian cancer, the treatment improved ... progression free survival by a median of 22.1
FDA sets June decision date for Tecentriq monotherapy in NSCLC
It is indicated for use in combination with chemotherapy and Roche’s older cancer antibody Avastin (bevacizumab) as a first-line treatment for non-squamous NSCLC.
Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD
Roche’s cancer drug Avastin (bevacizumab).
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- Regeneron says antibody for COVID-19 could be ready this year
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Amgen adds Otezla to the COVID-19 candidate list
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- Impetus Digital Fireside Chat with Susanne Somerville of Chronicled
- Impetus Digital Fireside Chat with Bechara Saab of Mobio Interactive
- FDA delays review of Novartis’ MS drug ofatumumab
- Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma
- Q&A: Kay Wesley
PMHub
Research Partnership
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
